Japan approves Bayer sales of Eylea for diabetes-related visual impairment

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved Bayer's Eylea for the treatment of diabetes-related visual impairment, the company said in a release issued June 26. Eylea has already been approved in Japan for the treatment of other types of vision loss, with Bayer and Regeneron ($REGN) holding varied rights for the drug. In this case, the Bayer Healthcare Japan unit received the latest Eylea approval. Release